Retatrutide Research
Retatrutide is a triple agonist peptide that engages the GIP, GLP-1, and glucagon receptors, used in laboratory research to study multi-receptor incretin and energy-expenditure signaling in in-vitro and experimental models.
Also known as: LY3437943 · triple-receptor agonist
Retatrutide is a synthetic peptide engineered for balanced activation of three class B GPCRs: the GIP, GLP-1, and glucagon receptors. In reported pharmacology it is markedly more potent at the GIP receptor and comparatively less potent at the glucagon and GLP-1 receptors relative to their native ligands. The added glucagon component is studied for its contribution to energy-expenditure pathways.
Receptor Activity
Retatrutide is studied as a single peptide capable of co-activating three distinct but structurally related receptors. Research characterization reports that it is roughly an order of magnitude more potent at the GIP receptor than native GIP, while acting as a partial-to-moderate agonist at the glucagon and GLP-1 receptors. This tri-agonist balance makes it a unique probe for investigating how simultaneous glucagon, GLP-1, and GIP signaling integrate at the cellular level. Researchers use it to study cAMP output across the three receptor systems, relative agonist potency, and the signaling cross-talk that arises when one ligand recruits multiple GPCR pathways in transfected cells and isolated tissue preparations.
Research Applications
In experimental research models, retatrutide is investigated for its combined effects on energy intake and energy expenditure, with the glucagon-receptor component studied as a driver of increased metabolic rate alongside GLP-1/GIP-mediated appetite signaling. Experimental studies have examined endpoints including food intake, body composition, gastric emptying, and lipid metabolism. Research hepatic models have also explored triple-agonist activity in steatotic-liver paradigms. Retatrutide commonly serves as a comparator against dual and single incretin agonists to isolate the contribution of glucagon-receptor signaling. All applications are research-use-only investigations in cell systems and experimental models.
Comparative Profile
Retatrutide occupies the most pharmacologically complex position in the incretin tool-compound class: where semaglutide is a single GLP-1 agonist and tirzepatide a dual GIP/GLP-1 agonist, retatrutide adds glucagon-receptor activity to create a triple-receptor probe. This makes it especially useful in comparative study designs that aim to dissect the distinct and overlapping roles of all three receptors. As a lyophilized peptide it follows standard laboratory handling: desiccated storage at -20 °C, preparation with sterile or bacteriostatic water, aliquoting to minimize freeze-thaw cycles, and refrigerated working solutions used within a limited window.
Applications at a glance
- Triple GIP/GLP-1/glucagon receptor agonist tool compound
- Experimental energy-expenditure and energy-balance models
- Comparative multi-receptor incretin signaling studies
- Research hepatic / lipid-metabolism studies